Cardiotoxicity in childhood cancer survivors: A problem with long-term consequences in need of early detection and prevention

Lipshultz, Steven E.; Franco, Vivian I.; Cochran, Thomas R.

doi:10.1002/pbc.24597

Cited by 10 publications

(9 citation statements)

References 9 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advances in treatment have increased survival in children with cancer, but their cardiovascular-related health burden will increase as this population grows and ages (46, 51, 53, 87, 93, 94). The developing field of pediatric cardio-oncology helps clinicians identify and understand the damage to the cardiovascular system caused by cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Cardiovascular Disease in Adult Survivors of Childhood Cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

Treatment advances have increased survival in children with cancer, but subclinical, progressive, irreversible, and sometimes fatal treatment-related cardiovascular effects may appear years later. Cardio-oncologists have identified promising preventive and treatment strategies. Dexrazoxane provides long-term cardioprotection from doxorubicin-associated cardiotoxicity without compromising the efficacy of anticancer treatment. Continuous infusion of doxorubicin is as effective as bolus administration in leukemia treatment, but no evidence has indicated that it provides long-term cardioprotection; continuous infusions should be eliminated from pediatric cancer treatment. Angiotensin-converting enzyme inhibitors can delay the progression of subclinical and clinical cardiotoxicity. All survivors, regardless of whether they were treated with anthracyclines or radiation, should be monitored for systemic inflammation and the risk of premature cardiovascular disease. Echocardiographic screening must be supplemented with screening for biomarkers of cardiotoxicity and perhaps by identification of genetic susceptibilities to cardiovascular diseases; optimal strategies need to be identified. The health burden related to cancer treatment will increase as this population expands and ages.

show abstract

Section: Discussionmentioning

confidence: 99%

Cardiovascular Disease in Adult Survivors of Childhood Cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…Generally, chemotherapy-induced cardiotoxicity is broadly divided into two types, type I and type II. Type I is more severe and thought to be irreversible, which is classically associated with anthracycline drugs such as doxorubicin, daunorubicin, epirubicin, and idarubicin (Lipshultz et al, 2013 ; Ai et al, 2014 ; Zamorano et al, 2016 ). While, type II toxicity is thought to be less severe and potentially reversible, and associated with non-anthracycline drugs (O'Hare et al, 2015 ; Zamorano et al, 2016 ).…”

Section: Chemotherapy Induced Cardiotoxicitymentioning

confidence: 99%

Protective Mechanism of Hydrogen Sulfide against Chemotherapy-Induced Cardiotoxicity

Huang

Jin

et al. 2018

Front. Pharmacol.

View full text Add to dashboard Cite

Over the past few decades, the number of long term survivors of childhood cancers has been increased exponentially. However, among these survivors, treatment-related toxicity, especially cardiotoxicity, is becoming the essential cause of morbidity and mortality. Thus, preventing the treatment-related adverse effects is important to increase the event free survival during the treatment of cancer in children and adolescents. Accumulating evidence has demonstrated that hydrogen sulfide (H2S) exerts a protective role on cardiomyocytes through a variety of mechanisms. Here, we mainly reviewed the cardioprotective role of H2S in the chemotherapy, and emphatically discussed the possible mechanisms.

show abstract

“…9 Furthermore, in the absence of overt HF in childhood, even small changes in ejection fraction from chemotherapy in childhood predispose adult survivors of childhood cancer to HF as they age. 10 Studies indicate that the pathogenesis underlying chemotherapy-related cardiovascular changes operates on a cellular level. [11][12][13] While this affects people of all ages, it is likely that the impact of chemotherapy treatment on a heart which is still developing will be different to that on a mature organ.…”

Section: Introductionmentioning

confidence: 99%